Related Experiment Video
Updated: Aug 19, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a
Daniela Pohl1, Kevin Rostasy, Jutta Gärtner
1Department of Pediatrics and Pediatric Neurology, Georg-August-University Goettingen, Robert-Koch-Strasse 40, 37075 Germany.
Abstract:
The authors studied the tolerability of subcutaneous interferon beta-1a (IFNbeta-1a) in 51 patients with early-onset multiple sclerosis. The most frequent systemic adverse effects were flu-like symptoms in 65%. Laboratory abnormalities included asymptomatic leukopenia (27%) and elevated hepatic transaminases (35%). Treatment with IFNbeta-1a was safe and well tolerated in the majority of children and adolescents.
Related Concept Videos
Multiple Sclerosis l: Introduction
Inhibitors of Viral Protein Synthesis
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
